TY - JOUR
T1 - Personal digital assistant-based drug information sources
T2 - Potential to improve medication safety
AU - Galt, Kimberly A.
AU - Rule, Ann M.
AU - Houghton, Bruce
AU - Young, Daniel O.
AU - Remington, Gina
PY - 2005/4/1
Y1 - 2005/4/1
N2 - Objectives: This study compared the potential for personal digital assistant (PDA)-based drug information sources to minimize potential medication errors dependent on accurate and complete drug information at the point of care. Methods: A quality and safety framework for drug information resources was developed to evaluate 11 PDA-based drug information sources. Three drug information sources met the criteria of the framework: Eprocrates Rx Pro, Lexi-Drugs, and mobileMICROMEDEX. Medication error types related to drug information at the point of care were then determined. Forty-seven questions were developed to test the potential of the sources to prevent these error types. Pharmacists and physician experts from Creighton University created these questions based on the most common types of questions asked by primary care providers. Three physicians evaluated the drug information sources, rating the source for each question: 1 = no information available, 2 = some information available, or 3 = adequate amount of information available. Results: The mean ratings for the drug information sources were: 2.0 (Eprocrates Rx Pro), 2.5 (Lexi-Drugs), and 2.03 (mobileMICROMEDEX). Lexi-Drugs was significantly better (mobileMICROMEDEX t test; P = 0.05; Eprocrates Rx Pro t test; P = 0.01). Conclusion: Lexi-Drugs was found to be the most specific and complete PDA resource available to optimize medication safety by reducing potential errors associated with drug information. No resource was sufficient to address the patient safety information needs for all cases.
AB - Objectives: This study compared the potential for personal digital assistant (PDA)-based drug information sources to minimize potential medication errors dependent on accurate and complete drug information at the point of care. Methods: A quality and safety framework for drug information resources was developed to evaluate 11 PDA-based drug information sources. Three drug information sources met the criteria of the framework: Eprocrates Rx Pro, Lexi-Drugs, and mobileMICROMEDEX. Medication error types related to drug information at the point of care were then determined. Forty-seven questions were developed to test the potential of the sources to prevent these error types. Pharmacists and physician experts from Creighton University created these questions based on the most common types of questions asked by primary care providers. Three physicians evaluated the drug information sources, rating the source for each question: 1 = no information available, 2 = some information available, or 3 = adequate amount of information available. Results: The mean ratings for the drug information sources were: 2.0 (Eprocrates Rx Pro), 2.5 (Lexi-Drugs), and 2.03 (mobileMICROMEDEX). Lexi-Drugs was significantly better (mobileMICROMEDEX t test; P = 0.05; Eprocrates Rx Pro t test; P = 0.01). Conclusion: Lexi-Drugs was found to be the most specific and complete PDA resource available to optimize medication safety by reducing potential errors associated with drug information. No resource was sufficient to address the patient safety information needs for all cases.
UR - http://www.scopus.com/inward/record.url?scp=23844525727&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=23844525727&partnerID=8YFLogxK
M3 - Article
C2 - 15858626
AN - SCOPUS:23844525727
VL - 93
SP - 229
EP - 236
JO - Journal of the Medical Library Association : JMLA
JF - Journal of the Medical Library Association : JMLA
SN - 1536-5050
IS - 2
ER -